利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.027 秒)

    Liquid crystalline polymers
    1.
    发明授权
    Liquid crystalline polymers 有权
    液晶聚合物

    公开(公告)号：US06696075B2

    公开(公告)日：2004-02-24

    申请号：US10231723

    申请日：2002-08-30

    申请人： Edith Mathiowitz ,  Jules S. Jacob ,  Yong S. Jong ,  Donald E. Chickering ,  Edwin E. Edwards

    发明人： Edith Mathiowitz ,  Jules S. Jacob ,  Yong S. Jong ,  Donald E. Chickering ,  Edwin E. Edwards

    IPC分类号： A61F1300

    CPC分类号： C09K19/38 ,  B29C55/00 ,  B29C55/18 ,  B29K2105/0079

    摘要： Methods for inducing a thermoplastic polymer, which can be non-mesogenic, to exhibit liquid crystalline properties have been developed. The method includes the steps of (a) heating the polymer from an initial temperature below its glass transition temperature (Tg) to a temperature greater than its Tg and below its melting temperature (Tm); (b) exposing the polymer to a pressure greater than about 2 metric tons/in2, preferably between about 2 and 10 metric tons/in2, preferably for at least about one minute, while maintaining the temperature greater than its Tg; and (c) cooling the polymer below the Tg while maintaining the elevated pressure. Unlike many prior art transition processes which are reversible, this process provides a liquid crystal state that can be maintained for years at ambient conditions. In a preferred embodiment, the plastics are bioerodible thermoplastic polymers, such as polyanhydrides, some polyesters, polyamides, and polyaromatics. The liquid crystalline polymers can be used in the controlled release or retention of substances encapsulated in the polymers. The polymer can be in a variety of forms including films, film laminants, and microparticles. In a preferred embodiment, the LC polymers are used to encapsulate therapeutic, diagnostic, or prophylactic agents for use in medical or pharmaceutical applications.

    摘要翻译： 已经开发了用于诱导可以是非介晶的热塑性聚合物以显示液晶性质的方法。 该方法包括以下步骤：（a）将聚合物从低于其玻璃化转变温度（Tg）的初始温度加热至大于其Tg并低于其熔融温度（Tm）的温度; （b）将聚合物暴露于大于约2公吨/ in 2的压力下，优选在约2至10公吨/ in 2之间，优选至少约1分钟，同时保持温度高于其 Tg; 和（c）在保持升高的压力的同时将聚合物冷却至Tg以下。 与可逆的许多现有技术的过渡过程不同，该方法提供可在环境条件下保持多年的液晶状态。 在优选的实施方案中，塑料是可生物腐蚀的热塑性聚合物，例如聚酐，一些聚酯，聚酰胺和多芳族化合物。 液晶聚合物可用于控制或保留包封在聚合物中的物质。 聚合物可以是各种形式，包括膜，膜层压剂和微粒。 在优选的实施方案中，LC聚合物用于包封用于医疗或药物应用的治疗剂，诊断剂或预防剂。

    Liquid crystalline polymers
    5.
    发明授权
    Liquid crystalline polymers 有权
    液晶聚合物

    公开(公告)号：US06465002B1

    公开(公告)日：2002-10-15

    申请号：US09523887

    申请日：2000-03-13

    申请人： Edith Mathiowitz ,  Jules S. Jacob ,  Yong S. Jong ,  Donald E. Chickering, III ,  Edwin E. Edwards

    发明人： Edith Mathiowitz ,  Jules S. Jacob ,  Yong S. Jong ,  Donald E. Chickering, III ,  Edwin E. Edwards

    IPC分类号： A61F1300

    CPC分类号： C09K19/38 ,  B29C55/00 ,  B29C55/18 ,  B29K2105/0079

    摘要： Methods for inducing a thermoplastic polymer, which can be non-mesogenic, to exhibit liquid crystalline properties have been developed. The method includes the steps of (a) heating the polymer from an initial temperature below its glass transition temperature (Tg) to a temperature greater than its Tg and below its melting temperature (Tm); (b) exposing the polymer to a pressure greater than about 2 metric tons/in2, preferably between about 2 and 10 metric tons/in2, preferably for at least about one minute, while maintaining the temperature greater than its Tg; and (c) cooling the polymer below the Tg while maintaining the elevated pressure. Unlike many prior art transition processes which are reversible, this process provides a liquid crystal state that can be maintained for years at ambient conditions. In a preferred embodiment, the plastics are bioerodible thermoplastic polymers, such as polyanhydrides, some polyesters, polyamides, and polyaromatics. The liquid crystalline polymers can be used in the controlled release or retention of substances encapsulated in the polymers. The polymer can be in a variety of forms including films, film laminants, and microparticles. In a preferred embodiment, the LC polymers are used to encapsulate therapeutic, diagnostic, or prophylactic agents for use in medical or pharmaceutical applications.

    摘要翻译： 已经开发了用于诱导可以是非介晶的热塑性聚合物以显示液晶性质的方法。 该方法包括以下步骤：（a）将聚合物从低于其玻璃化转变温度（Tg）的初始温度加热至大于其Tg并低于其熔融温度（Tm）的温度; （b）将聚合物暴露于大于约2公吨/ in2的压力下，优选约2至10公吨/ in 2，优选至少约1分钟，同时保持温度高于其Tg; 和（c）在保持升高的压力的同时将聚合物冷却至Tg以下。 与可逆的许多现有技术的过渡过程不同，该方法提供可在环境条件下保持多年的液晶状态。 在优选的实施方案中，塑料是可生物腐蚀的热塑性聚合物，例如聚酐，一些聚酯，聚酰胺和多芳族化合物。 液晶聚合物可用于控制或保留包封在聚合物中的物质。 聚合物可以是各种形式，包括膜，膜层压剂和微粒。 在优选的实施方案中，LC聚合物用于包封用于医疗或药物应用的治疗剂，诊断剂或预防剂。

    Micronized freeze-dried particles
    8.
    发明授权
    Micronized freeze-dried particles 有权

    公开(公告)号：US07029700B2

    公开(公告)日：2006-04-18

    申请号：US09760046

    申请日：2001-01-12

    申请人： Edith Mathiowitz ,  Yong S. Jong ,  Jules S. Jacob

    发明人： Edith Mathiowitz ,  Yong S. Jong ,  Jules S. Jacob

    IPC分类号： A61K9/14 ,  A61K9/50

    CPC分类号： A61K9/5153 ,  A61K9/1641 ,  A61K9/1647 ,  A61K9/1694 ,  A61K9/5192

    摘要： A process is provided for making dry, micronized particles of an agent, such as a drug. The method includes (a) dissolving a macromolecular material, preferably a polymer, in an effective amount of a solvent, to form a solution; (b) dissolving or dispersing the agent in the solution to form a mixture; (c) freezing the mixture; and (d) drying by vacuum the mixture to form solid particles of the agent dispersed in solid macromolecular material. The micronization in this process occurs directly in a macromolecular matrix and hardening of the particles of agent by solvent removal takes place by lyophilization of the bulk matrix, which stabilizes the drug particles during hardening and prevents coalesence, thereby resulting in smaller final drug particles. The method is particularly preferred for protein agents. The process can be used in conjunction with a standard microencapsulation technique, typically following separation of the agent from the macromolecular matrix. The process yields microparticles having a homogenous size distribution, preferably less than 2 μm, and more preferably less than 1 μm, in size. The microparticles have well defined, predictable properties, which is particularly critical in drug delivery applications.